Annals of Colorectal Research

Published by: Kowsar

Inappropriate Total Oxidant/Antioxidant Status, Nitric Oxide Oxidation End Products and Trace Element Levels in Patients with Inflammatory Bowel Disease

Erfan Mohammadi 1 , 2 , Durdi Qujeq 3 , * , Hassan Taheri 4 and Karimollah Hajian-Tilaki 5
Authors Information
1 Cellular and Molecular Biology Research Center (CMBRC), Health Research Institute, Babol University of Medical Sciences, Babol, IR Iran
2 Student Research Committee, Babol University of Medical Sciences, Babol, IR Iran
3 Department of Clinical Biochemistry, Babol University of Medical Sciences, Babol, IR Iran
4 Department of Internal Medicine, Gastroenterology Division, Ayatollah Rouhani Hospital, Babol University of Medical Sciences, Babol, IR Iran
5 Department of Biostatistics and Epidemiology, Babol University of Medical Sciences, Babol, IR Iran
Article information
  • Annals of Colorectal Research: March 2018, 6 (1); e64029
  • Published Online: March 31, 2018
  • Article Type: Research Article
  • Received: December 11, 2017
  • Revised: March 1, 2018
  • Accepted: March 18, 2018
  • DOI: 10.5812/acr.64029

To Cite: Mohammadi E, Qujeq D, Taheri H, Hajian-Tilaki K. Inappropriate Total Oxidant/Antioxidant Status, Nitric Oxide Oxidation End Products and Trace Element Levels in Patients with Inflammatory Bowel Disease, Ann Colorectal Res. 2018 ; 6(1):e64029. doi: 10.5812/acr.64029.

Abstract
Copyright © 2018, Annals of Colorectal Research. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Methods
3. Results
4. Discussion
5. Limitation
6. Conclusions
Acknowledgements
Footnotes
References
  • 1. Kaistha A, Levine J. Inflammatory bowel disease: the classic gastrointestinal autoimmune disease. Curr Probl Pediatr Adolesc Health Care. 2014;44(11):328-34. doi: 10.1016/j.cppeds.2014.10.003. [PubMed: 25499459].
  • 2. Longobardi T, Bernstein CN. Utilization of health-care resources by patients with IBD in Manitoba: a profile of time since diagnosis. Am J Gastroenterol. 2007;102(8):1683-91. doi: 10.1111/j.1572-0241.2007.01232.x. [PubMed: 17459026].
  • 3. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1785-94. doi: 10.1053/j.gastro.2011.01.055. [PubMed: 21530745].
  • 4. Talley NJ, Abreu MT, Achkar JP, Bernstein CN, Dubinsky MC, Hanauer SB, et al. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol. 2011;106 Suppl 1:S2-25. quiz S26. doi: 10.1038/ajg.2011.58. [PubMed: 21472012].
  • 5. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46-54 e42. quiz e30. doi: 10.1053/j.gastro.2011.10.001. [PubMed: 22001864].
  • 6. Tonutti E, Agostinis P, Bizzaro N. Inflammatory bowel diseases: where we are and where we should go. Clin Chem Lab Med. 2014;52(4):463-5. doi: 10.1515/cclm-2014-0146. [PubMed: 24583463].
  • 7. Sobczak M, Fabisiak A, Murawska N, Wesolowska E, Wierzbicka P, Wlazlowski M, et al. Current overview of extrinsic and intrinsic factors in etiology and progression of inflammatory bowel diseases. Pharmacol Rep. 2014;66(5):766-75. doi: 10.1016/j.pharep.2014.04.005. [PubMed: 25149979].
  • 8. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007;369(9573):1627-40. doi: 10.1016/S0140-6736(07)60750-8. [PubMed: 17499605].
  • 9. Engel MA, Khalil M, Neurath MF. Highlights in inflammatory bowel disease--from bench to bedside. Clin Chem Lab Med. 2012;50(7):1229-35. [PubMed: 23024984].
  • 10. Saijo F, Milsom AB, Bryan NS, Bauer SM, Vowinkel T, Ivanovic M, et al. On the dynamics of nitrite, nitrate and other biomarkers of nitric oxide production in inflammatory bowel disease. Nitric Oxide. 2010;22(2):155-67. doi: 10.1016/j.niox.2009.11.009. [PubMed: 20005300].
  • 11. Kolios G, Valatas V, Ward SG. Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle. Immunology. 2004;113(4):427-37. doi: 10.1111/j.1365-2567.2004.01984.x. [PubMed: 15554920]. [PubMed Central: PMC1782592].
  • 12. Kimura H, Hokari R, Miura S, Shigematsu T, Hirokawa M, Akiba Y, et al. Increased expression of an inducible isoform of nitric oxide synthase and the formation of peroxynitrite in colonic mucosa of patients with active ulcerative colitis. Gut. 1998;42(2):180-7. [PubMed: 9536941]. [PubMed Central: PMC1727005].
  • 13. Ljung T, Beijer E, Herulf M, Weitzberg E, Lundberg JO, Finkel Y, et al. Increased rectal nitric oxide in children with active inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2002;34(3):302-6. [PubMed: 11964958].
  • 14. Ljung T, Lundberg S, Varsanyi M, Johansson C, Schmidt PT, Herulf M, et al. Rectal nitric oxide as biomarker in the treatment of inflammatory bowel disease: responders versus nonresponders. World J Gastroenterol. 2006;12(21):3386-92. [PubMed: 16733856]. [PubMed Central: PMC4087870].
  • 15. Janero DR. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radic Biol Med. 1990;9(6):515-40. [PubMed: 2079232].
  • 16. Piechota-Polanczyk A, Fichna J. Review article: the role of oxidative stress in pathogenesis and treatment of inflammatory bowel diseases. Naunyn Schmiedebergs Arch Pharmacol. 2014;387(7):605-20. doi: 10.1007/s00210-014-0985-1. [PubMed: 24798211]. [PubMed Central: PMC4065336].
  • 17. Baskol G, Baskol M, Yurci A, Ozbakir O, Yucesoy M. Serum paraoxonase 1 activity and malondialdehyde levels in patients with ulcerative colitis. Cell Biochem Funct. 2006;24(3):283-6. doi: 10.1002/cbf.1224. [PubMed: 15830398].
  • 18. Kurutas EB, Cetinkaya A, Bulbuloglu E, Kantarceken B. Effects of antioxidant therapy on leukocyte myeloperoxidase and Cu/Zn-superoxide dismutase and plasma malondialdehyde levels in experimental colitis. Mediators Inflamm. 2005;2005(6):390-4. doi: 10.1155/MI.2005.390. [PubMed: 16489261]. [PubMed Central: PMC1533903].
  • 19. Tuzun A, Erdil A, Inal V, Aydin A, Bagci S, Yesilova Z, et al. Oxidative stress and antioxidant capacity in patients with inflammatory bowel disease. Clin Biochem. 2002;35(7):569-72. [PubMed: 12493587].
  • 20. Speckmann B, Steinbrenner H. Selenium and selenoproteins in inflammatory bowel diseases and experimental colitis. Inflamm Bowel Dis. 2014;20(6):1110-9. doi: 10.1097/MIB.0000000000000020. [PubMed: 24694793].
  • 21. Rayman MP. Selenium and human health. Lancet. 2012;379(9822):1256-68. doi: 10.1016/S0140-6736(11)61452-9. [PubMed: 22381456].
  • 22. Reeves MA, Hoffmann PR. The human selenoproteome: recent insights into functions and regulation. Cell Mol Life Sci. 2009;66(15):2457-78. doi: 10.1007/s00018-009-0032-4. [PubMed: 19399585]. [PubMed Central: PMC2866081].
  • 23. Achitei D, Ciobica A, Balan G, Gologan E, Stanciu C, Stefanescu G. Different profile of peripheral antioxidant enzymes and lipid peroxidation in active and non-active inflammatory bowel disease patients. Dig Dis Sci. 2013;58(5):1244-9. doi: 10.1007/s10620-012-2510-z. [PubMed: 23306840].
  • 24. Prabhu KS, Zamamiri-Davis F, Stewart JB, Thompson JT, Sordillo LM, Reddy CC. Selenium deficiency increases the expression of inducible nitric oxide synthase in RAW 264.7 macrophages: role of nuclear factor-kappaB in up-regulation. Biochem J. 2002;366(Pt 1):203-9. doi: 10.1042/BJ20020256. [PubMed: 12006087]. [PubMed Central: PMC1222757].
  • 25. Weiss G. Iron and immunity: a double-edged sword. Eur J Clin Invest. 2002;32 Suppl 1:70-8. [PubMed: 11886435].
  • 26. Wessling-Resnick M. Iron homeostasis and the inflammatory response. Annu Rev Nutr. 2010;30:105-22. doi: 10.1146/annurev.nutr.012809.104804. [PubMed: 20420524]. [PubMed Central: PMC3108097].
  • 27. Schaible UE, Kaufmann SH. Iron and microbial infection. Nat Rev Microbiol. 2004;2(12):946-53. doi: 10.1038/nrmicro1046. [PubMed: 15550940].
  • 28. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989;298(6666):82-6. [PubMed: 2563951]. [PubMed Central: PMC1835436].
  • 29. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet. 1980;1(8167):514. [PubMed: 6102236].
  • 30. Huber M, Knottnerus JA, Green L, van der Horst H, Jadad AR, Kromhout D, et al. How should we define health? BMJ. 2011;343:d4163. doi: 10.1136/bmj.d4163. [PubMed: 21791490].
  • 31. Rael LT, Thomas GW, Craun ML, Curtis CG, Bar-Or R, Bar-Or D. Lipid peroxidation and the thiobarbituric acid assay: standardization of the assay when using saturated and unsaturated fatty acids. J Biochem Mol Biol. 2004;37(6):749-52. [PubMed: 15607036].
  • 32. Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal Biochem. 1996;239(1):70-6. doi: 10.1006/abio.1996.0292. [PubMed: 8660627].
  • 33. Qujeq D, Aliakbarpour HR, Kalavi K. Relationship between malondialdehyde level and glutathione peroxidase activity in diabetic rats. Clin Chim Acta. 2004;340(1-2):79-83. [PubMed: 14734198].
  • 34. Qujeq D, Habibinudeh M, Daylmkatoli H, Rezvani T. Malondialdehyde and carbonyl contents in the erythrocytes of streptozotocin-induced diabetic rats. Int J Diabetes Metabol. 2005;13:96-8.
  • 35. Qujeq D, Hidari B, Bijani K, Shirdel H. Glutathione peroxidase activity and serum selenium concentration in intrinsic asthmatic patients. Clin Chem Lab Med. 2003;41(2):200-2. doi: 10.1515/CCLM.2003.032. [PubMed: 12667007].
  • 36. Mohammadi E, Qujeq D, Taheri H, Hajian-Tilaki K. Evaluation of Serum Trace Element Levels and Superoxide Dismutase Activity in Patients with Inflammatory Bowel Disease: Translating Basic Research into Clinical Application. Biol Trace Elem Res. 2017;177(2):235-40. doi: 10.1007/s12011-016-0891-0. [PubMed: 27864666].
  • 37. Moein S, Qujeq D, Vaghari Tabari M, Kashifard M, Hajian-Tilaki K. Diagnostic accuracy of fecal calprotectin in assessing the severity of inflammatory bowel disease: From laboratory to clinic. Caspian J Intern Med. 2017;8(3):178-82. doi: 10.22088/cjim.8.3.178. [PubMed: 28932369]. [PubMed Central: PMC5596188].
  • 38. Hofseth LJ. Nitric oxide as a target of complementary and alternative medicines to prevent and treat inflammation and cancer. Cancer Lett. 2008;268(1):10-30. doi: 10.1016/j.canlet.2008.03.024.
  • 39. Jadert C, Phillipson M, Holm L, Lundberg JO, Borniquel S. Preventive and therapeutic effects of nitrite supplementation in experimental inflammatory bowel disease. Redox Biol. 2014;2:73-81. doi: 10.1016/j.redox.2013.12.012. [PubMed: 24494186]. [PubMed Central: PMC3909265].
  • 40. Rogers JA, Fuseler JW. Regulation of NF-kappaB activation and nuclear translocation by exogenous nitric oxide (NO) donors in TNF-alpha activated vascular endothelial cells. Nitric Oxide. 2007;16(3):379-91. doi: 10.1016/j.niox.2007.02.001. [PubMed: 17374495].
  • 41. Glover LE, Colgan SP. Hypoxia and metabolic factors that influence inflammatory bowel disease pathogenesis. Gastroenterology. 2011;140(6):1748-55. doi: 10.1053/j.gastro.2011.01.056. [PubMed: 21530741]. [PubMed Central: PMC3093411].
  • 42. Olson N, van der Vliet A. Interactions between nitric oxide and hypoxia-inducible factor signaling pathways in inflammatory disease. Nitric Oxide. 2011;25(2):125-37. doi: 10.1016/j.niox.2010.12.010. [PubMed: 21199675]. [PubMed Central: PMC3090692].
  • 43. Raat NJ, Shiva S, Gladwin MT. Effects of nitrite on modulating ROS generation following ischemia and reperfusion. Adv Drug Deliv Rev. 2009;61(4):339-50. [PubMed: 19385092].
  • 44. Wiskin AE, Fleming BJ, Wootton SA, Beattie RM. Anaemia and iron deficiency in children with inflammatory bowel disease. J Crohns Colitis. 2012;6(6):687-91. doi: 10.1016/j.crohns.2011.12.001. [PubMed: 22398100].
  • 45. Loitsch SM, Diehl D, Hartmann F, Dignass AU, Stein J. Impaired Intestinal Iron Absorption in Inflammatory Bowel Disease Correlates With Disease Activity and Markers of Inflammation but is Independent of Disease Location. Gastroenterology. 2011;140(5):S-5. doi: 10.1016/s0016-5085(11)60020-6.
  • 46. Stein J, Dignass AU. Management of iron deficiency anemia in inflammatory bowel disease - a practical approach. Ann Gastroenterol. 2013;26(2):104-13. [PubMed: 24714874]. [PubMed Central: PMC3959949].
  • 47. Murr C, Pilz S, Grammer TB, Kleber ME, Bohm BO, Marz W, et al. Low serum zinc levels in patients undergoing coronary angiography correlate with immune activation and inflammation. J Trace Elem Med Biol. 2012;26(1):26-30. doi: 10.1016/j.jtemb.2011.11.004. [PubMed: 22365070].
  • 48. Cimen MY. Free radical metabolism in human erythrocytes. Clin Chim Acta. 2008;390(1-2):1-11. doi: 10.1016/j.cca.2007.12.025. [PubMed: 18243141].
  • 49. Vaghari Tabari M, Moein S, Qujeq D, Kashifard M, Shokri J. Examination of the Potential Antioxidant Role of High-Density Lipoprotein-Cholesterol (HDL-C) in Patients with Ulcerative Colitis. Measurement. 2017;4:22.
  • 50. Kruidenier L, Kuiper I, Lamers CB, Verspaget HW. Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants. J Pathol. 2003;201(1):28-36. doi: 10.1002/path.1409. [PubMed: 12950014].
  • 51. Rezaie A, Parker RD, Abdollahi M. Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig Dis Sci. 2007;52(9):2015-21. doi: 10.1007/s10620-006-9622-2. [PubMed: 17404859].
  • 52. Geerling BJ, Badart-Smook A, van Deursen C, van Houwelingen AC, Russel MG, Stockbrugger RW, et al. Nutritional supplementation with N-3 fatty acids and antioxidants in patients with Crohn's disease in remission: effects on antioxidant status and fatty acid profile. Inflamm Bowel Dis. 2000;6(2):77-84. [PubMed: 10833065].
  • 53. Barrett CW, Singh K, Motley AK, Lintel MK, Matafonova E, Bradley AM, et al. Dietary selenium deficiency exacerbates DSS-induced epithelial injury and AOM/DSS-induced tumorigenesis. PLoS One. 2013;8(7). e67845. doi: 10.1371/journal.pone.0067845. [PubMed: 23861820]. [PubMed Central: PMC3701622].
  • 54. Vaghari-Tabari M, Moein S, Qujeq D, Kashifard M, Hajian-Tilaki K. Positive Correlation of Fecal Calprotectin With Serum Antioxidant Enzymes in Patients With Inflammatory Bowel Disease: Accidental Numerical Correlation or a New Finding? Am J Med Sci. 2018;355(5):449-55. doi: 10.1016/j.amjms.2017.12.009. [PubMed: 29753375].
  • 55. Gentschew L, Bishop KS, Han DY, Morgan AR, Fraser AG, Lam WJ, et al. Selenium, selenoprotein genes and Crohn's disease in a case-control population from Auckland, New Zealand. Nutrients. 2012;4(9):1247-59. doi: 10.3390/nu4091247. [PubMed: 23112913]. [PubMed Central: PMC3475235].
  • 56. Johtatsu T, Andoh A, Kurihara M, Iwakawa H, Tsujikawa T, Kashiwagi A, et al. Serum concentrations of trace elements in patients with Crohn's disease receiving enteral nutrition. J Clin Biochem Nutr. 2007;41(3):197-201. doi: 10.3164/jcbn.2007028. [PubMed: 18299716]. [PubMed Central: PMC2243248].
  • 57. Galan-Chilet I, Tellez-Plaza M, Guallar E, De Marco G, Lopez-Izquierdo R, Gonzalez-Manzano I, et al. Plasma selenium levels and oxidative stress biomarkers: a gene-environment interaction population-based study. Free Radic Biol Med. 2014;74:229-36. doi: 10.1016/j.freeradbiomed.2014.07.005. [PubMed: 25017966].
  • 58. Tirosh O, Levy E, Reifen R. High selenium diet protects against TNBS-induced acute inflammation, mitochondrial dysfunction, and secondary necrosis in rat colon. Nutrition. 2007;23(11-12):878-86. doi: 10.1016/j.nut.2007.08.019. [PubMed: 17936198].
  • 59. Rock C, Moos PJ. Selenoprotein P protects cells from lipid hydroperoxides generated by 15-LOX-1. Prostaglandins Leukot Essent Fatty Acids. 2010;83(4-6):203-10. doi: 10.1016/j.plefa.2010.08.006. [PubMed: 20826080]. [PubMed Central: PMC2993840].
  • 60. Pavlick KP, Laroux FS, Fuseler J, Wolf RE, Gray L, Hoffman J, et al. Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease. Free Radic Biol Med. 2002;33(3):311-22. [PubMed: 12126753].
  • 61. Loguercio C, D'Argenio G, Delle Cave M, Cosenza V, Della Valle N, Mazzacca G, et al. Glutathione supplementation improves oxidative damage in experimental colitis. Dig Liver Dis. 2003;35(9):635-41. [PubMed: 14563185].
  • 62. Oz HS, Chen TS, McClain CJ, de Villiers WJ. Antioxidants as novel therapy in a murine model of colitis. J Nutr Biochem. 2005;16(5):297-304. doi: 10.1016/j.jnutbio.2004.09.007. [PubMed: 15866230].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments